Tirzepatide vs Semaglutide: GLP-1 Weight Loss Comparison
A detailed comparison of tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy, Rybelsus), the two most prescribed incretin-based weight loss medications. Covers mechanism, head-to-head trial data, cardiovascular outcomes, oral availability, cost, and side-effect profiles.
Last updated: 2026-04-15
| Property | Tirzepatide | Semaglutide |
|---|---|---|
| Evidence Level | Level A | Level A |
| Regulatory Status | FDA ApprovedFDA-approved May 2022 (Mounjaro) for type 2 diabetes; FDA-approved November 2023 (Zepbound) for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related comorbidity. | FDA ApprovedFDA-approved December 2017 (Ozempic) for type 2 diabetes; FDA-approved June 2021 (Wegovy, 2.4 mg) for chronic weight management; FDA-approved September 2019 (Rybelsus, oral) for type 2 diabetes. |
| Category | Weight Management | Weight Management |
| Administration | Injectable | Injectable, Oral |
| Onset Time | Appetite suppression onset within days to weeks; peak weight loss at 36–72 weeks | Appetite suppression onset within days to weeks; peak weight loss at 52–68 weeks |
| Half-Life | Approximately 5 days (once-weekly dosing) | Approximately 7 days (once-weekly injectable dosing) |
| Key Mechanism | Tirzepatide's metabolic effects arise from simultaneous activation of two distinct incretin hormone receptors: GLP... | Semaglutide activates the GLP-1 receptor, a G protein-coupled receptor expressed in the pancreas, brain, gut, heart, ... |
Tirzepatide
- Evidence Level
- Level A
- Regulatory Status
- FDA ApprovedFDA-approved May 2022 (Mounjaro) for type 2 diabetes; FDA-approved November 2023 (Zepbound) for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related comorbidity.
- Category
- Weight Management
- Administration
- Injectable
- Onset Time
- Appetite suppression onset within days to weeks; peak weight loss at 36–72 weeks
- Half-Life
- Approximately 5 days (once-weekly dosing)
- Key Mechanism
- Tirzepatide's metabolic effects arise from simultaneous activation of two distinct incretin hormone receptors: GLP...
Semaglutide
- Evidence Level
- Level A
- Regulatory Status
- FDA ApprovedFDA-approved December 2017 (Ozempic) for type 2 diabetes; FDA-approved June 2021 (Wegovy, 2.4 mg) for chronic weight management; FDA-approved September 2019 (Rybelsus, oral) for type 2 diabetes.
- Category
- Weight Management
- Administration
- Injectable, Oral
- Onset Time
- Appetite suppression onset within days to weeks; peak weight loss at 52–68 weeks
- Half-Life
- Approximately 7 days (once-weekly injectable dosing)
- Key Mechanism
- Semaglutide activates the GLP-1 receptor, a G protein-coupled receptor expressed in the pancreas, brain, gut, heart, ...
Key Differences
Tirzepatide and semaglutide are both FDA-approved once-weekly injectables used for type 2 diabetes and chronic weight management, but they differ in receptor pharmacology, magnitude of efficacy, formulation options, and cardiovascular evidence base. They are the two most widely prescribed incretin-based therapies and represent the current standard of care in obesity pharmacotherapy.
Mechanism of Action
Semaglutide is a selective GLP-1 receptor agonist. It binds GLP-1 receptors in the pancreas (enhancing glucose-dependent insulin secretion and suppressing glucagon), the hypothalamus (reducing appetite and food-reward signaling), and the gut (slowing gastric emptying). It does not meaningfully engage the GIP receptor.
Tirzepatide is a dual GLP-1/GIP receptor agonist. It activates both incretin receptors with a pharmacology engineered to favor GIP binding while still providing potent GLP-1 signaling. The addition of GIP receptor activation is proposed to contribute to greater reductions in food intake, improved insulin sensitivity, and favorable effects on adipose tissue metabolism. Whether GIP agonism, GIP antagonism, or partial/biased signaling is the mechanistic driver of GIP's metabolic benefit remains an area of active research, but the clinical efficacy of the dual agonist is well established.
Head-to-Head Efficacy: SURPASS-2
SURPASS-2 (NEJM, 2021) is the only large randomized head-to-head trial comparing the two drugs. In 1,879 adults with type 2 diabetes, tirzepatide (5, 10, or 15 mg weekly) was compared against semaglutide 1 mg weekly over 40 weeks. All three tirzepatide doses produced significantly greater reductions in HbA1c and body weight than semaglutide 1 mg. Mean weight loss on tirzepatide 15 mg was approximately 11.2 kg versus approximately 5.7 kg on semaglutide 1 mg. Note: SURPASS-2 used the type 2 diabetes dose of semaglutide (1 mg), not the higher 2.4 mg obesity dose used in STEP-1 and Wegovy.
Obesity Trial Efficacy: SURMOUNT-1 vs STEP-1
In the obesity trials, tirzepatide 15 mg produced a mean body weight reduction of approximately 22.5% over 72 weeks in SURMOUNT-1, while semaglutide 2.4 mg produced a mean reduction of approximately 14.9% over 68 weeks in STEP-1. These trials were not head-to-head and used different populations and durations, so direct efficacy comparison requires caution, but the effect sizes are meaningfully different and have held up in subsequent SURMOUNT and STEP trials.
Cardiovascular Outcomes
Semaglutide has the stronger cardiovascular evidence base. The SELECT trial (NEJM, 2023) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in 17,604 adults with established cardiovascular disease and obesity without diabetes — making semaglutide the first obesity medication with proven CV benefit in a non-diabetic population, and the basis for Wegovy's expanded CV risk reduction indication in 2024. Tirzepatide's SURPASS-CVOT trial completed 2024–2025; topline results support non-inferiority versus dulaglutide for MACE in type 2 diabetes, but full results and any superiority findings in obesity without diabetes are still being published.
Oral Formulation
Semaglutide has a substantial formulation advantage: Rybelsus is the only FDA-approved oral GLP-1 receptor agonist. It uses the SNAC absorption enhancer to achieve oral bioavailability and is approved for type 2 diabetes. Tirzepatide is injectable-only, though Eli Lilly's orforglipron (an oral small-molecule GLP-1 agonist, not tirzepatide itself) is in late-stage development.
Cost and Access
U.S. list prices are similar — both in the $1,000–$1,350 per month range at launch pricing — and both have faced supply constraints since 2022. Insurance coverage patterns diverge meaningfully: Ozempic and Wegovy have longer formulary history and broader commercial coverage, while Zepbound and Mounjaro coverage has been growing since approval but remains less universal. Medicare does not cover either drug specifically for obesity (though both are covered for type 2 diabetes when medically indicated). Both manufacturers offer cash-pay programs, and compounded versions of both drugs proliferated during shortages — the FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in early 2025, which restricts the legal basis for most compounded versions.
Side Effect Profile
The two drugs share a similar overall side-effect profile, dominated by gastrointestinal effects (nausea, vomiting, diarrhea, constipation) that are most prominent during dose escalation and typically diminish with continued use. Both carry a boxed warning for thyroid C-cell tumors based on rodent data, are contraindicated in personal or family history of medullary thyroid carcinoma and MEN 2 syndrome, and carry warnings for pancreatitis, gallbladder disease, and acute kidney injury secondary to volume depletion. Incidence of severe GI effects appears broadly comparable between the two drugs in trials, though individual tolerability varies and some patients who do not tolerate one drug tolerate the other.
Which Is Better For...?
Maximum weight loss as the primary goal — SURMOUNT-1 produced a mean 22.5% body weight reduction at the 15 mg dose, the largest effect size of any FDA-approved obesity medication to date, and SURPASS-2 showed superior weight and HbA1c reductions versus semaglutide 1 mg in type 2 diabetes.
Type 2 diabetes with suboptimal HbA1c control on other therapies — SURPASS program data consistently show larger HbA1c reductions than GLP-1 monotherapy, with the 15 mg dose producing mean HbA1c reductions of approximately 2.0–2.3 percentage points.
Cardiovascular risk reduction in adults with obesity and established cardiovascular disease — the SELECT trial established a 20% MACE reduction in adults with obesity and CVD without diabetes, a benefit not yet established for tirzepatide in the non-diabetic population.
Patients who need or prefer an oral option — Rybelsus is the only FDA-approved oral GLP-1 agonist, which can be important for patients with injection aversion or logistical barriers to weekly injections, though it is currently approved for type 2 diabetes rather than weight management.
Broader formulary access and longer real-world safety record — semaglutide has been on market since 2017 (Ozempic) and benefits from a longer post-approval safety database and generally wider commercial insurance coverage than tirzepatide.